ZVRA logo

ZVRA
Zevra Therapeutics Inc

24,022
Mkt Cap
$546.09M
Volume
1,799.00
52W High
$13.16
52W Low
$6.19
PE Ratio
15.38
ZVRA Fundamentals
Price
$9.70
Prev Close
$9.18
Open
$9.18
50D MA
$9.62
Beta
0.95
Avg. Volume
1.71M
EPS (Annual)
-$2.28
P/B
4.09
Rev/Employee
$400,203.39
Loading...
Loading...
News
all
press releases
Campbell & CO Investment Adviser LLC Buys Shares of 83,245 Zevra Therapeutics, Inc. $ZVRA
Campbell & CO Investment Adviser LLC purchased a new position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the second quarter, according to its most recent Form 13F filing with the...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Los Angeles Capital Management LLC Buys Shares of 121,225 Zevra Therapeutics, Inc. $ZVRA
Los Angeles Capital Management LLC purchased a new stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F...
MarketBeat·5d ago
News Placeholder
Research Analysts Set Expectations for ZVRA FY2025 Earnings
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Investment analysts at William Blair lifted their FY2025 earnings estimates for Zevra Therapeutics in a research report issued to clients and...
MarketBeat·9d ago
News Placeholder
FY2025 EPS Estimate for Zevra Therapeutics Raised by Analyst
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities researchers at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for Zevra Therapeutics in a note issued to...
MarketBeat·9d ago
News Placeholder
William Blair Analysts Boost Earnings Estimates for ZVRA
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - William Blair lifted their Q3 2026 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a report issued on Wednesday, November...
MarketBeat·11d ago
News Placeholder
FY2026 EPS Estimates for ZVRA Decreased by Cantor Fitzgerald
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities research analysts at Cantor Fitzgerald cut their FY2026 EPS estimates for shares of Zevra Therapeutics in a note issued to investors on...
MarketBeat·11d ago
News Placeholder
Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to "Buy" at Wall Street Zen
Wall Street Zen upgraded Zevra Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday...
MarketBeat·11d ago
News Placeholder
Zevra Therapeutics (NASDAQ:ZVRA) Given New $24.00 Price Target at Cantor Fitzgerald
Cantor Fitzgerald decreased their price target on shares of Zevra Therapeutics from $29.00 to $24.00 and set an "overweight" rating for the company in a research note on Thursday...
MarketBeat·12d ago
News Placeholder
Zevra Therapeutics (NASDAQ:ZVRA) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate...
MarketBeat·13d ago
News Placeholder
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +75.00% and -1.77%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago

Latest ZVRA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.